A first-in-class bladder cancer chemoablation launch (now unblocked by a permanent J-code) creates asymmetric upside—if UroGen can convert urologists from surgery to office-based drug therapy fast enough.
Overview
UroGen Pharma is a commercial-stage biopharma focused on non-surgical, localized therapies for urothelial and specialty urologic cancers—diseases historically managed with repeated invasive procedures and high recurrence. The company’s foundation is RTGel, a reverse-thermal hydrogel delivery system designed to keep chemotherapy in contact with urinary tract tissue for longer, improving local efficacy while limiting systemic exposure. UroGen has transitioned from a single-product company to a two-franchise uro-oncology business with two FDA-approved products: (1) JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC), a steady revenue base; and (2) ZUSDURI, FDA-approved June 12, 2025, the first and only pharmacologic treatment specifically for adults with recurrent low-grade intermediate-risk NMIBC (LG-IR-NMIBC), and the central future growth driver. In FY2025, revenue grew 21% to $109.8M (JELMYTO $94.0M; ZUSDURI $15.8M), demonstrating early commercial transformation despite ZUSDURI launch friction from lack of a permanent reimbursement code for much of the year. Commercial strategy hinges on expanding beyond hospital outpatient departments into community urology clinics, which manage the highest NMIBC patient volumes; in 2025, ~60% of ZUSDURI treatments were hospital-based, with a goal to reach a ~50/50 hospital/community mix as adoption matures. The company is positioning ZUSDURI to disrupt the TURBT surgical paradigm by offering outpatient chemoablation that can extend disease-free intervals, pursuing a management-estimated >$5B total addressable market.